54
Participants
Start Date
April 5, 2022
Primary Completion Date
June 27, 2025
Study Completion Date
October 30, 2025
ManNAc
Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
Placebo
Placebo
Columbia University Medical Center, New York
University of Rochester, Rochester
NIH Clinical Center, Bethesda
Ohio State University, Wexner Medical Center, Columbus
University of Iowa, Iowa City
Washington University, St Louis
University of Kansas, Medical Center, Kansas City
University of Utah, Salt Lake City
UCLA, Los Angeles
Brigham and Women's Hospital, Boston
Lead Sponsor
Brigham and Women's Hospital
OTHER
National Human Genome Research Institute (NHGRI)
NIH
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
NIH (NIAMS and NIND) as part of NeuroNext
UNKNOWN
Leadiant Biosciences, Inc.
INDUSTRY